UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 27, 2011
|
|
|
Enzo Biochem, Inc. |
|
|
|
(Exact Name of Registrant as Specified in Its Charter) |
|
|
|
New York |
|
|
|
(State or Other Jurisdiction of Incorporation) |
|
|
|
|
001-09974 |
13-2866202 |
|
|
|
|
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
527 Madison Avenue |
|
|
New York, New York |
10022 |
|
|
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
|
|
(212) 583-0100 |
|
|
|
(Registrant’s Telephone Number, Including Area Code) |
|
|
|
|
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 27, 2011, Dr. Kevin Krenitsky resigned as President of Enzo Clinical Labs, a wholly-owned subsidiary of Enzo Biochem, Inc. (the “Company”). Dr. Krenitsky did not resign because of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Krenitsky has left Enzo Clinical Labs to pursue another business opportunity. Dr. Krenitsky’s responsibilities at the Enzo Clinical Labs organization will be assumed by Mr. David C. Goldberg, the Company’s Vice President, Corporate Development.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
ENZO BIOCHEM, INC. |
|
|
|
|
|
|
Date: June 3, 2011 |
By: |
/s/ Barry Weiner |
|
|
|
|
|
|
|
Barry Weiner |
|
|
|
President, Chief Financial Officer, |
|
|
|
Principal Accounting Officer and Director |